Antibody-guided irradiation of advanced ovarian cancer with intraperitoneal monoclonal antibodies

Journal Article · Mon Nov 30 23:00:00 EST 1987 · J. Clin. Oncol.; (United States)

OSTI ID:5604140

Epenetos, A A; Munro, A J; Stewart, S; Rampling, R; Lambert, H E; McKenzie, C G; Soutter, P; Rahemtulla, A; Hooker, G; Sivolapenko, G B

Twenty-four patients with persistent epithelial ovarian cancer after chemotherapy with or without external beam irradiation, were treated with intraperitoneally administered /sup 131/I-labeled monoclonal antibodies HMFG1, HMFG2, AUA1, H17E2, directed against tumor-associated antigens. Acute side effects were mild abdominal pain, pyrexia, diarrhea, and moderate reversible pancytopenia. One patient developed a subphrenic abscess requiring surgical drainage. Eight patients with large volume disease, ie, greater than 2 cm tumor diameter, did not respond to antibody-guided irradiation and died of progressive disease within 9 months of treatment. Sixteen patients had small-volume (less than 2 cm) disease at the time of treatment with radiolabeled antibody. Seven patients failed to respond, and of nine initial responders, four patients remain alive and free from disease 6 months to 3 years from treatment. Analysis of the data on relapse indicated that doses greater than 140 mCi were more effective than lower doses. We conclude that the intraperitoneal administration of 140 mCi or more of /sup 131/I-labeled tumor-associated monoclonal antibodies represents a new and potentially effective form of therapy for patients with small-volume stage III ovarian cancer.

• Research Organization: Royal Postgraduate Medical School, London, England
• OSTI ID: 5604140
• Journal Information: J. Clin. Oncol.; (United States), Journal Name: J. Clin. Oncol.; (United States) Vol. 5:12; ISSN JCOND
• Country of Publication: United States
• Language: English

Related Subjects

550604* -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIBODIES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BIOLOGICAL HALF-LIFE
BODY
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
FEMALE GENITALS
GONADS
INJECTION
INTAKE
INTERMEDIATE MASS NUCLEI
INTRAPERITONEAL INJECTION
IODINE 131
IODINE ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
MEDICINE
MONOCLONAL ANTIBODIES
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ORGANS
OVARIES
PATIENTS
RADIATION DOSES
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
THERAPEUTIC USES
THERAPY
USES